XTLB
XTL Biopharmaceuticals Ltd.
There isn't enough reported data to score XTLB yet.
XTLB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Stable | |
| Strong |
XTLB's balance sheet is currently strong, and its cash flow is stable, but its profitability is under pressure. There isn't enough data to rate its revenue.
XTLB PE Valuation
XTLB has no meaningful PE right now: it lost money over the past year.
XTLB Forward outlook
There aren't enough analyst estimates for XTLB to show an outlook.
XTLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.88 | +$2.40 |
| Q3 2024 | -$3.04 | +$3.68 |
| Q2 2024 | -$2.08 | +$6.40 |
| Q1 2024 | -$1.12 | +$7.04 |
| Q4 2023 | -$5.28 | -$1.28 |
| Q3 2023 | -$6.72 | -262% |
| Q2 2023 | -$8.48 | -266% |
| Q1 2023 | -$8.16 | -343% |
XTLB is still losing money, but far less than before: $2.88 per share over the past year, against $16.16 at its worst in early 2020.
XTLB Quarterly Revenue
XTLB's revenue is growing: $289,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -281% | N/A |
| Q3 2024 | -472% | N/A |
XTLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
| Q2 2024 | $0 | $0 |
| Q1 2024 | $0 | $0 |
| Q4 2023 | $0 | $0 |
| Q3 2023 | $0 | $0 |
| Q2 2023 | $0 | $0 |
| Q1 2023 | $0 | $0 |
XTLB's free cash flow has been positive every quarter for six years: $0 over the past year, against $0 the year before.
XTLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +29% | +99.5K shares |
| 1 year | +29% | +99.5K shares |
| 3 years | +22% | +79.7K shares |
| 5 years | +37% | +119K shares |
| Available history | +37% | +119K shares |
XTLB has 440,101 diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
XTLB hasn't bought back shares in the past year.
XTLB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -6.6x | Net Cash |
| Q3 2018 | -0.9x | Net Cash |
| Q2 2018 | -2.6x | Net Cash |
XTLB has more cash than debt.
XTLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 2.2 | Oversold |
XTLB's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
XTLB PE vs Healthcare Sector
| Metric | XTLB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XTLB has no meaningful PE right now: it lost money over the past year.
XTLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.89 | 13% below |
| 20 week MA | $2.39 | 31% below |
| 50 week MA | $2.69 | 39% below |
| 100 week MA | $4.01 | 59% below |
| 200 week MA | $5.16 | 68% below |
XTLB is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
XTLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.20 | $11.0 | +112% |
| 2021 | $11.0 | $10.9 | -1.1% |
| 2022 | $10.9 | $4.76 | -56% |
| 2023 | $4.76 | $4.04 | -15% |
| 2024 | $4.04 | $8.28 | +105% |
| 2025 | $8.28 | $2.96 | -64% |
| 2026 YTD | $2.96 | $1.64 | -45% |
XTLB's yearly returns have swung widely, from +112% in 2020 to −64% in 2025. It's down 45% so far in 2026.